Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.